To investigate this, we performed DAb-seq on 21,952 total cells from bone marrow aspirates of a patient with AML receiving gemtuzumab, a CD33-targeted therapy, across four treatment timepoints (Fig. 3a). This evidence concerns the gene CD33 and acute myeloid leukemia.